{
  "id": 5039985,
  "title": "Alteogen signs deal with Novartis worth up to 4.4 tln won for subcutaneous formulations",
  "url": "https://urgent.news/2026/09/02/alteogen-signs-deal-with-novartis-worth-up-to-4-4-tln-won-for",
  "topic": "world",
  "section": "World",
  "published": "2026-09-02T06:49:23.000Z",
  "source": {
    "name": "Yonhap News",
    "slug": "yonhap-news",
    "url": "https://en.yna.co.kr/view/AEN20260902007500320"
  },
  "original_language": "en",
  "account": null,
  "summary": "SEOUL, Sept. 2 (Yonhap) -- South Korean biotechnology company Alteogen Inc. said...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "The Korea Times",
        "title": "Alteogen signs deal with Novartis worth up to $3.2 bil. for subcutaneous formulations",
        "url": "https://urgent.news/2026/09/02/alteogen-signs-deal-with-novartis-worth-up-to-3-2-bil-for",
        "published": "2026-09-02T07:22:03.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}